| Literature DB >> 33716960 |
Cetin Sari1, Richard L Seip1,2, Devika Umashanker1,3.
Abstract
FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m2 prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period.Entities:
Keywords: MBSAQIP surgical risk calculator; anti-obesity pharmacotherapy; generic weight loss medications; medical weight loss; pre-surgery; preoperative weight loss; super obesity
Mesh:
Substances:
Year: 2021 PMID: 33716960 PMCID: PMC7947603 DOI: 10.3389/fendo.2021.588016
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555